NC
TGTX icon

NewSquare Capital’s TG Therapeutics TGTX Stock Holding History

NewSquare Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16
Closed -$576 – 1126
2025
Q2 		$576 Buy
+16
New +$596 ﹤0.01% 1128

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NewSquare Capital's TGTX Position: Q3 2025 in Review

NewSquare Capital sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 16 shares — an estimated $576 sold.

NewSquare Capital first reported a position in TGTX in Q2 2025 and held it in 1 quarter. The position peaked at $576 in Q2 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

  • NewSquare Capital reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
  • NewSquare Capital sold 16 TG Therapeutics shares in Q3 2025, an estimated $576.
  • NewSquare Capital first reported a position in TG Therapeutics in Q2 2025 and held it in 1 quarter.
  • NewSquare Capital's TG Therapeutics position peaked at $576 in Q2 2025.
  • 354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on NewSquare Capital's 13F filing for Q3 2025, filed 12 Nov 2025.